Company · Public · NTLA
Intellia Therapeutics
Clinical-stage genome editing company with in vivo CRISPR programmes in amyloidosis and hereditary angioedema.
Listing
Public
Ticker
NTLA
Headquarters
Cambridge, US
Founded
2014
Technology
In vivo CRISPR gene editing
Category
Longevity thesis
Durable in vivo editing turns chronic disease management into single-administration treatment — the delivery template later longevity interventions will need.
Programmes
- NTLA-2002Phase 3
Hereditary angioedema
- nex-zPhase 3
ATTR amyloidosis
Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.